Laura Esserman discusses breast cancer risk factors, progress in the field and the importance of tailoring treatment for women with low-risk cancer while also identifying women at high risk of invasive cancer.
Zuranolone (Zurzuvae), the first pill for patients suffering from postpartum depression, is expected to be available by the end of 2023. Though it may relieve depressive symptoms, it has some drawbacks such as sedation and dangers in breastfeeding.
UCSF researchers are working across disease specialties. Diabetes researchers are looking at how oncologists use CAR T-cell therapy to reprogram a person’s immune system to attack cancer cells, for example. They hope to similarly reprogram the immune system to fight diabetes.
UCSF primary care physician and researcher Alka M. Kanaya, MD, is being recognized with the 2023 Kelly West Award for Outstanding Achievement in Epidemiology from the American Diabetes Association (ADA).
Two UCSF scientists – James Gardner, MD, PhD, and Rebeca de Pavia Fróes Rocha, PhD – have received Pew awards for their work in immunology as part of a program that supports promising early-career investigators.
UCSF researchers tested nitroglycerin patches, an treatment for chest pain from coronary artery disease, for menopausal hot flashes. Short-term benefits were seen, but not long-term as some side effects occurred.